Press Releases Mar 15 2023 Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates Read More Mar 14 2023 Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting Read More Mar 12 2023 Kinnate Biopharma Inc. Provides Statement on Silicon Valley Bank Receivership Read More View All Upcoming Events Apr 17 2023 at 5:30 PM EDT Apr 17 2023 at 5:30 PM EDT Kinnate Biopharma AACR 2023 virtual Investor Event Read More View All
Mar 15 2023 Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates Read More
Mar 14 2023 Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting Read More
Apr 17 2023 at 5:30 PM EDT Apr 17 2023 at 5:30 PM EDT Kinnate Biopharma AACR 2023 virtual Investor Event Read More
